Berna Akinci Ozyurek1, Tugce Sahin Ozdemirel1, Sertac Buyukyaylaci Ozden1, Yurdanur Erdoğan1, Ozlem Ozmen2, Bekir Kaplan3, Tugba Kaplan4. 1. Chest Diseases Clinic, Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey. 2. Nuclear Medicine Clinic, Ataturk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey. 3. Bloomberg School of Public Health, Johns Hopkins University, Maryland. 4. Chest Diseases, Ulus State Hospital, Ankara, Turkey.
Abstract
BACKGROUND: Lung cancer is the most commonly diagnosed and death-related cancer type and is more frequent in males. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all case. In this study, it was aimed to research the relationship between advanced lung inflammation index (ALI) and the primary mass maximum standardized uptake value (SUVmax) and C-reactive protein (CRP) at initial diagnosis and the prognostic value of ALI in determining the survival in metastatic NSCLC. METHODS: A total of 112 patients diagnosed as stage 4 non-small-lung cancer in our hospital between January 2006 and December 2013 were included in this study. ALI was calculated as body mass index (BMI) × serum albumin/neutrophil-to-lymphocyte ratio (NLR). The patients were divided into two groups as ALI < 18 (high inflammation) and ALI ≥ 18 (low inflammation). The log-rank test and Cox proportional hazard model were used to identify predictors of mortality. RESULTS: Evaluation was made of 94 male and 18 female patients with a mean age of 59.7 ± 9.9 years. A statistically significant negative relationship was determined between ALI and CRP values (P < .001), but no relationship was found between ALI and SUVmax values (P = .436). The median survival time in patients with ALI < 18 was 12 months and, in those with ALI ≥ 18, it was 16 months (P = .095). CONCLUSION: ALI is an easily calculated indicator of inflammation in lung cancer patients. Values <18 can be considered to predict a poor prognosis.
BACKGROUND: Lung cancer is the most commonly diagnosed and death-related cancer type and is more frequent in males. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all case. In this study, it was aimed to research the relationship between advanced lung inflammation index (ALI) and the primary mass maximum standardized uptake value (SUVmax) and C-reactive protein (CRP) at initial diagnosis and the prognostic value of ALI in determining the survival in metastatic NSCLC. METHODS: A total of 112 patients diagnosed as stage 4 non-small-lung cancer in our hospital between January 2006 and December 2013 were included in this study. ALI was calculated as body mass index (BMI) × serum albumin/neutrophil-to-lymphocyte ratio (NLR). The patients were divided into two groups as ALI < 18 (high inflammation) and ALI ≥ 18 (low inflammation). The log-rank test and Cox proportional hazard model were used to identify predictors of mortality. RESULTS: Evaluation was made of 94 male and 18 female patients with a mean age of 59.7 ± 9.9 years. A statistically significant negative relationship was determined between ALI and CRP values (P < .001), but no relationship was found between ALI and SUVmax values (P = .436). The median survival time in patients with ALI < 18 was 12 months and, in those with ALI ≥ 18, it was 16 months (P = .095). CONCLUSION: ALI is an easily calculated indicator of inflammation in lung cancerpatients. Values <18 can be considered to predict a poor prognosis.
Authors: Dominik Andreas Barth; Carina Brenner; Jakob Michael Riedl; Felix Prinz; Eva Valentina Klocker; Konstantin Schlick; Peter Kornprat; Karoline Lackner; Herbert Stöger; Michael Stotz; Armin Gerger; Martin Pichler Journal: Cancer Med Date: 2020-06-14 Impact factor: 4.711